Misa Shimpo

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

Criterion validity of the visual estimation method for determining patients' meal intake in a community hospital

Yui Kawasaki, Masashi Sakai, Kazuhiro Nishimura et al. · Clinical Nutrition · 2016 · 62 citations

Food Choice, Nutrition, Body Composition +12

Factors Associated with Dietary Change since the Outbreak of COVID-19 in Japan

Misa Shimpo, Rie Akamatsu, Yui Kojima et al. · Nutrients · 2021 · 39 citations · Full text

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki et al. · Journal of the Neurological Sciences · 2019 · 23 citations · Full text